Skip to content
Screener

Nektar Therapeutics NKTR Shares (Diluted)

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+20.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
69.7M+19.7%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
39.4M+61.7%
CTO
Citius Oncology, Inc.CTOR
100M+39.8%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.48B+539%
Enterprise value$2.56B+435%
P/S44.6×+39.4×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemThree Months Ended March 31,Three Months Ended March 31,Three Months Ended March 31,
Total non-operating income (expense), net(4,036)(1,834)
Loss before provision for income taxes and equity method investment(43,090)(46,369)
Provision for income taxes6452
Loss before equity method investment(43,154)(46,421)
Loss from equity method investment(1,750)(4,461)
Net loss$$$(44,904)(50,882)
Basic and diluted net loss per share$$$(1.82)(3.62)
Weighted average shares outstanding used in computing basic and diluted net loss per share24,736,06614,063,402

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's shares (diluted)?
Nektar Therapeutics (NKTR) reported shares (diluted) of 24.7M in Q1 2026.
How has Nektar Therapeutics's shares (diluted) changed year-over-year?
Nektar Therapeutics's shares (diluted) increased by 75.9% year-over-year, from 14.1M to 24.7M.
What is the long-term trend for Nektar Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), Nektar Therapeutics's shares (diluted) has grown at a -45.6% compound annual growth rate (CAGR), from 731.5M to 64M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Nektar Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude